We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




New Hemodialysis Catheter Maintains Long-Term Patency

By HospiMedica International staff writers
Posted on 27 Apr 2021
Print article
Image: The Pristine Long-Term Hemodialysis Catheter (Photo courtesy of BD)
Image: The Pristine Long-Term Hemodialysis Catheter (Photo courtesy of BD)
An innovative hemodialysis catheter with a unique lumen design can maintain primary patency rates for up to 180 days.

The BD (Franklin Lakes, NJ, USA) Pristine Long-Term 15.5F hemodialysis catheter boasts a side-hole free symmetric Y-Tip distal lumen, which is aimed to minimize thrombus adhesion (a problem commonly associated with side-hole catheters), facilitate blood clot aspiration prior to hemodialysis, and minimize recirculation rates in both forward and reverse flows. In a prospective feasibility study, which followed 45 patients who received the Pristine Catheter for six months, all catheters were patent at 60-days, and 90.9% remained patent at 180-days post procedure.

“The BD Pristine Catheter adds to our diversified portfolio of products in support of clinicians who care for patients with end stage kidney disease (ESKD) who require hemodialysis,” said Padraic O'Brien, worldwide president of peripheral intervention at BD. “This exciting technology is highly complementary to our current ESKD portfolio, and will enable us to offer a differentiated product that can help to improve the patient experience.”

“A majority of hemodialysis patients in the United States start their treatment with a catheter, and many of those catheter-dependent patients will suffer a catheter-related complication at some point during treatment, which can adversely impact the patient and create additional healthcare system costs,” said Michael Tal, MD, founder of Pristine Access Technologies (Israel), and inventor of the Pristine Catheter. “The Pristine Catheter was designed with hemodialysis patients in mind and to help address some of these concerns.”

While an arteriovenous fistula (AVF) remains the preferred access option for patients on hemodialysis therapy, these often can take four months or longer to mature, and a catheter is often required during this time period; but more than 40% of such patients develop a venous obstruction. Many patients, in fact, prefer a catheter over an AVF, for reasons that include inadequate preparation for dialysis, phobia or avoidance of surgery, or fear of needles (since the connection to the dialysis machine via a catheter does not require needles).

Related Links:
BD

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Electric Bariatric Patient Lifter
SVBL 205

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.